Cell fractions containing cells capable of differentiating into neural cells

Abstract

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

1 . A mononuclear cell fraction containing cells capable of differentiating into neural cells, wherein said fraction is isolated from bone marrow cells or cord blood cells collected from vertebrate. 
     
     
         2 . The cell fraction according to  claim 1 , which can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 2,000 rpm in a solution for a sufficient time ensuring separation depending on specific gravity, and then recovering the cell fraction within the range of a specific gravity of 1.07 to 1.1 g/ml. 
     
     
         3 . A mononuclear cell fraction isolated from bone marrow cells of cord blood cells collected from vertebrate, wherein the fraction contains cells having the character SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−), CD34(−), and CD45(−), and are capable of differentiating into neural cells. 
     
     
         4 . A mononuclear cell fraction isolated from bone marrow cells of cord blood cells collected from vertebrate, wherein the fraction contains cells having the character SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−), CD34(−), and CD45(−), and are capable of differentiating into neural cells, which can be prepared by recovering cells having the character SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−), CD34(−), and CD45(−), from the cell fraction according to  claim 2 . 
     
     
         5 . The cell fraction according to  claim 3 , which can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 900 G in a solution for a sufficient time ensuring separation depending on specific gravity, and then recovering the cell fraction within the range of a specific gravity of 1.07 to 1.1 g/ml. 
     
     
         6 . A mononuclear cell fraction containing cells isolated from bone marrow cells or cord blood cells collected from vertebrate, wherein the fraction contains cells having the character Lin(−), Sca-1(+), CD10(+), CD11D(+), CD44(+), CD45(+), CD71(+), CD90(+), CD105(+), CDW123(+), CD127(+), CD164(+), fibronectin(+), ALPH(+), and collagenase-1(+), and are capable of differentiating into neural cells. 
     
     
         7 . A mononuclear cell fraction containing cells isolated from bone marrow cells or cord blood cells collected from vertebrate, wherein the fraction contains cells having the character Lin(−), Sca-1(+), CD10(+), CD11D(+), CD44(+), CD45(+), CD71(+), CD90(+), CD105(+), CDW123(+), CD127(+), CD164(+), fibronectin(+), ALPH(+), and collagenase-1(+), and are capable of differentiating into neural cells, which can be prepared by recovering cells having the character Lin(−), Sca-1(+), CD10(+), CD11D(+), CD44(+), CD45(+), CD71(+), CD90(+), CD105(+), CDW123(+), CD127(+), CD164(+), fibronectin(+), ALPH(+), and collagenase-1(+) from the cell fraction according to  claim 2 . 
     
     
         8 . The cell fraction according to  claim 6 , which can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 800 G in a solution for a sufficient time ensuring separation depending on specific gravity, and then recovering the cell fraction within the range of a specific gravity of 1.07 to 1.1 g/ml. 
     
     
         9 . A mononuclear cell fraction isolated from bone marrow cells, cord blood cells, or embryonic hepatic tissues collected from vertebrate, wherein the fraction contains cells characterized by AC133(+), and are capable of differentiating into neural cells. 
     
     
         10 . The cell fraction according to  claim 9 , which can be prepared by subjecting bone marrow cells, cord blood cells, or embryonic hepatic tissues collected from vertebrate to density-gradient centrifugation at 2,000 rpm in a solution for a sufficient time ensuring separation depending on specific gravity, recovering a cell fraction within the range of a specific gravity of 1.07 to 1.1 g/ml, and then recovering cells characterized by AC133(+) from the cell fraction. 
     
     
         11 . A cell capable of differentiating into neural cells, which is contained in the cell fraction according to  claim 1 . 
     
     
         12 . A composition for treating neurological diseases, which comprises the cell fraction according to  claim 1 . 
     
     
         13 . The composition according to  claim 12 , wherein the neurological disease is selected from the group consisting of central and peripheral demyelinating diseases; central and peripheral degenerative diseases; cerebral apoplexy selected from cerebral infarction, cerebral hemorrhage, and subarachnoid hemorrhage; brain tumor; dysfunction of higher function of the brain; psychiatric diseases; epilepsy; traumatic neurological diseases; infectious diseases; and infarction of spinal cord. 
     
     
         14 . A method for treating neurological diseases, which comprises transplanting, into a recipient, the cell fraction according to  claim 1 . 
     
     
         15 . The therapeutic method according to  claim 14 , wherein the neurological disease is selected from the group consisting of central and peripheral demyelinating diseases; central and peripheral degenerative diseases; cerebral apoplexy selected from cerebral infarction, cerebral hemorrhage, and subarachnoid hemorrhage; brain tumor; dysfunction of higher function of the brain; psychiatric diseases; epilepsy; traumatic neurological diseases; infectious diseases; and infarction of spinal cord. 
     
     
         16 . The therapeutic method according to  claim 15 , wherein the cells to be transplanted are derived from the recipient. 
     
     
         17 . A composition for treating neurological diseases, which comprises the cell according to  claim 11 . 
     
     
         18 . A method for treating neurological diseases, which comprises transplanting, into a recipient, the cell according to  claim 11 . 
     
     
         19 . A method for treating neurological diseases, which comprises transplanting, into a recipient, the composition according to  claim 12 .